Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FL-802
- Development stage
- Preclinical
- Lead developer
- Full-Life Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
FL-802 is a preclinical-stage radionuclide drug conjugate (RDC) being developed by Full-Life Technologies. It targets B7-H3 (CD276), a transmembrane protein that is highly expressed in various solid tumors but has limited expression in normal tissues, making it an attractive target for cancer therapy. FL-802 utilizes Actinium-225 (Ac-225), an alpha-emitting radioisotope, to deliver targeted radiation to tumor cells, inducing DNA damage and cell death. The program is currently being evaluated for the treatment of several solid malignancies, including small cell lung cancer (SCLC), colorectal cancer (CRC), esophageal cancer, prostate cancer, and breast cancer.
02
Targets
B7-H3
Beyond the preview
Go deeper on FL-802.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FL-802.